P16INK4a impairs homologous recombination-mediated DNA repair in human papillomavirus-positive head and neck tumors

Cancer Research

Volumn 74, Issue 6, 2014, Pages 1739-1751

  Dok, Rüveyda ^a,g   Kalev, Peter ^b,e   Van Limbergen, Evert Jan ^a,f   Asbagh, Layka Abbasi ^c   Vázquez, Iria ^b,e   Hauben, Esther ^d   Sablina, Anna ^b,e   Nuyts, Sandra ^a,f  

^a Laboratory of Experimental Psychology   (Belgium)

^b Department of Human Genetics Laboratory for Mechanisms of Cell Transformation   (United States)

^c Department of Oncology Molecular and Digestive Oncology   (United States)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^f Departments of Radiation Oncology   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 2A; RAD51 PROTEIN;

ARTICLE; CANCER RADIOTHERAPY; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVITY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN TISSUE; IONIZING RADIATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIOSENSITIVITY; RECOMBINATION REPAIR; TREATMENT RESPONSE; WART VIRUS;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CHEMORADIOTHERAPY; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA DAMAGE; HEAD AND NECK NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; PAPILLOMAVIRUS INFECTIONS; RAD51 RECOMBINASE; RADIATION TOLERANCE; RECOMBINATIONAL DNA REPAIR; TREATMENT OUTCOME;

EID: 84896515405     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2479     Document Type: Article

References (49)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Fakhry C, Gillison ML. Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 2006;24:2606-11. (Pubitemid 46622080)
3. Lassen P. The role of human papillomavirus in head and neck cancer and the impact on radiotherapy outcome. Radiother Oncol 2010;95: 371-80.
4. Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, et al. Improved survival of patientswith human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100:261-9. (Pubitemid 351480538)
5. Marur S, Forastiere AA. Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc 2008;83:489-501. (Pubitemid 351536473)
6. Sellers WR, Rodgers JW, Kaelin WG Jr. A potent transrepression domain in the retinoblastoma protein induces a cell-cycle arrest when bound to E2F sites. Proc Natl Acad Sci U S A 1995;92:11544-8. (Pubitemid 26014150)
7. Bremner R, Cohen BL, Sopta M, Hamel PA, Ingles CJ, Gallie BL, et al. Direct transcriptional repression by pRB and its reversal by specific cyclins. Mol Cell Biol 1995;15:3256-65.
8. Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, et al. Molecular classification identifies a subset of human papillomavirus- Associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006;24:736-47. (Pubitemid 46622040)
9. Dirix P, Nuyts S. Evidence-based organ-sparing radiotherapy in head and neck cancer. Lancet Oncol 2010;11:85-91.
10. Nuyts S, Dirix P, Clement PM, Poorten VV, Delaere P, Schoenaers J, et al. Impact of adding concomitant chemotherapy to hyperfractionated accelerated radiotherapy for advanced head-And-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2009;73:1088-95.
11. Rieckmann T, Tribius S, Grob TJ, Meyer F, Busch CJ, Petersen C, et al. HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity. Radiother Oncol 2013;107:242-6.
12. Kimple RJ, Smith MA, Blitzer GC, Torres AD, Martin JA, Yang RZ, et al. Enhanced radiation sensitivity in HPV-positive head and neck cancer. Cancer Res 2013;73:4791-800.
13. Smeets SJ, HesselinkAT, Speel EJ, Haesevoets A, Snijders PJ, Pawlita M, et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 2007;121:2465-72. (Pubitemid 350022416)
14. De Schutter H, Kimpe M, Isebaert S, Nuyts S.Asystematic assessment of radiation dose enhancement by 5-Aza-20-deoxycytidine and histone deacetylase inhibitors in head-And-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2009;73:904-12.
15. Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, Hinkle G, et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 2006;124:1283-98.
16. Xu B, Kim ST, Lim DS, Kastan MB. Two molecularly distinct G(2)/M checkpoints are induced by ionizing irradiation. Mol Cell Biol 2002; 22:1049-59. (Pubitemid 34094842)
17. Mladenov E, Tsaneva I, Anachkova B. Cell-cycle-dependent association of Rad51 with the nuclear matrix. DNA Cell Biol 2007;26: 36-43. (Pubitemid 46219590)
18. Kalev P, Simicek M, Vazquez I, Munck S, Chen L, Soin T, et al. Loss of PPP2R2A inhibits homologous recombinationDNArepair and predicts tumor sensitivity to PARP inhibition. Cancer Res 2012;72:6414-24.
19. Seo HR, Lee DH, Lee HJ, Baek M, Bae S, Soh JW, et al. Cyclin G1 overcomes radiation-induced G2 arrest and increases cell death through transcriptional activation of cyclin B1. Cell Death Differ 2006; 13:1475-84. (Pubitemid 44210351)
20. Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J. Effect of HPV-Associated p16(INK4A) expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009;27:1992-8.
21. Cerqueira A, Santamaria D, Martinez-Pastor B, Cuadrado M, Fernandez-Capetillo O, Barbacid M. Overall Cdk activity modulates the DNA damage response in mammalian cells. J Cell Biol 2009;187:773-80.
22. Johnson N, Shapiro GI. Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors. Expert Opin Ther Targets 2010;14:1199-212.
23. Alvarez-Fernandez M, Halim VA, Krenning L, Aprelia M, Mohammed S, Heck AJ, et al. Recovery fromaDNAdamage-inducedG2arrest requires Cdk-dependent activation of FoxM1. EMBO Rep 2010;11:452-8.
24. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004;3:1427-38.
25. Toogood PL, Harvey PJ, Repine JT, Sheehan DJ, VanderWel SN, Zhou H, et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem 2005;48:2388-406. (Pubitemid 40516432)
26. Wiedemeyer WR, Dunn IF, Quayle SN, Zhang J, Chheda MG, Dunn GP, et al. Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. Proc Natl Acad Sci U S A 2010;107: 11501-6.
27. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-12. (Pubitemid 29297917)
28. Kaminagakura E, Werneck da Cunha I, Soares FA, Nishimoto IN, Kowalski LP. CCND1 amplification and protein overexpression in oral squamous cell carcinoma of young patients. Head Neck 2011;33: 1413-9.
29. Shimura T, Kakuda S,Ochiai Y, Nakagawa H, Kuwahara Y, Takai Y, et al. Acquired radioresistance of human tumor cells by DNA-PK/AKT/GSK3 beta-mediated cyclin D1 overexpression. Oncogene 2010;29:4826-37.
30. Milas L, Akimoto T, Hunter NR, Mason KA, Buchmiller L, Yamakawa M, et al. Relationship between cyclin D1 expression and poor radioresponse of murine carcinomas. Int J Radiat Oncol Biol Phys 2002;52: 514-21. (Pubitemid 34170856)
31. Chang AR,WuHG, Park CI, Jeon YK, Kim CW.Expression of epidermal growth factor receptor and cyclin D1 in pretreatment biopsies as a predictive factor of radiotherapy efficacy in early glottic cancer. Head Neck 2008;30:852-7. (Pubitemid 352008943)
32. Lai JP, Tong CL, Hong C, Xiao JY, Tao ZD, Zhang Z, et al. Association between high initial tissue levels of cyclin D1 and recurrence of nasopharyngeal carcinoma. Laryngoscope 2002;112:402-8. (Pubitemid 34135893)
33. Wang MB, Yip HT, Srivatsan ES. Antisense cyclin D1 enhances sensitivity of head and neck cancer cells to cisplatin. Laryngoscope 2001;111:982-8. (Pubitemid 32523704)
34. Jirawatnotai S, Hu Y, Michowski W, Elias JE, Becks L, Bienvenu F, et al. A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature 2011;474:230-4.
35. Li Z, Jiao X, Wang C, Shirley LA, Elsaleh H, Dahl O, et al. Alternative cyclin D1 splice forms differentially regulate the DNA damage response. Cancer Res 2010;70:8802-11.
36. Oliveira NG, Castro M, Rodrigues AS, Goncalves IC, Gil OM, Fernandes AP, et al. Wortmannin enhances the induction of micronuclei by low and high LET radiation. Mutagenesis 2003;18:37-44. (Pubitemid 36113606)
37. Fenech M. Micronuclei and their association with sperm abnormalities, infertility, pregnancy loss, preeclampsia and intrauterine growth restriction in humans. Mutagenesis 2011;26:63-7.
38. Burd CE, Sorrentino JA, Clark KS, Darr DB, Krishnamurthy J, Deal AM, et al. Monitoring tumorigenesis and senescence in vivo with a p16 (INK4a)-luciferase model. Cell 2013;152:340-51.
39. Anders L, Ke N, Hydbring P, Choi YJ, Widlund HR, Chick JM, et al. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell 2011; 20:620-34.
40. Lewis JS Jr. p16 Immunohistochemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma. Head Neck Pathol 2012;6:S75-82.
41. Lewis JS, Thorstad WL, Chernock RD, Haughey BH, Yip JH, Zhang Q, et al. p16-positive oropharyngeal squamous cell carcinoma: an entity with a favorable prognosis regardless of tumor HPV status. Am J Surg Pathol 2010;34:1088-96.
42. Zhao N, Ang MK, Yin XY, Patel MR, Fritchie K, Thorne L, et al. Different cellular p16(INK4a) localisation may signal different survival outcomes in head and neck cancer. Br J Cancer 2012;107: 482-90.
43. Hoffmann M, Tribius S, Quabius ES, Henry H, Pfannenschmidt S, Burkhardt C, et al. HPV DNA, E6I-mRNA expression and p16INK4A immunohistochemistry in head and neck cancer-how valid is p16INK4A as surrogate marker? Cancer Lett 2012;323:88-96.
44. Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 2008;8:671-82.
45. Shintani S, Mihara M, Ueyama Y, Matsumura T, Wong DT. Cyclin D1 overexpression associates with radiosensitivity in oral squamous cell carcinoma. Int J Cancer 2001;96:159-65. (Pubitemid 32520670)
46. Yoo SS, Carter D, Turner BC, Sasaki CT, Son YH, Wilson LD, et al. Prognostic significance of cyclin D1 protein levels in early-stage larynx cancer treated with primary radiation. Int J Cancer 2000;90: 22-8. (Pubitemid 30158973)
47. Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008;26:3582-9.
48. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24-35.
49. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer 2010;10:293-301.